| |
| |
|
| Insider
Information: |
Oneill Gilmore Neil |
| Relationship: |
CEO, Director |
| City: |
Cambridge |
| State: |
MA |
| |
|
| Insider
Summary: |
|
|
|
|
Companies Owned : |
2 |
|
| Direct
Shares |
356,016 |
|
|
Indirect Shares
|
0 |
|
|
| Direct
Value |
$5,527,932 |
|
|
|
Indirect Value
|
$0 |
|
|
| Total
Shares |
356,016 |
|
|
| Total
Value |
$5,527,932 |
|
|
|
|
|
|
|
|
Historical
Performance :
Based on 6 Month Return Percentages |
Buys
|
Sells
|
|
Total
Filings :
|
0
|
2
|
|
Stock
price went up :
|
0
|
0
|
| Stock
price went down : |
0
|
2
|
| |
|
|
|
Gain/Loss Ratio : |
0.0
|
-2.0
|
| Percentage
Gain/Loss : |
0.0%
|
 -58.9%
|
| |
|
|
|
|
|
Holdings
:
| Menu |
Company Name |
Ticker |
Relation |
Direct Date |
Direct Shares |
Indirect Date |
Indirect Shares |
Total Value Sold  |
 |
Sarepta Therapeutics Inc |
SRPT |
EVP, R&D & CMO |
2021-03-03 |
28,546 |
|
0 |
Premium* |
|
|
Editas Medicine, Inc. |
EDIT |
CEO, Director |
2024-03-05 |
327,470 |
2022-06-02 |
0 |
Premium* |
|
|
|
|
|
|
|
|
|
|
|
Records found :
11 |
Free Registration Required For Full Results. Limit: 25
|
 |
Download |
Page 1 of 1
|
| Ticker |
Company Name |
Relation |
Off-Dir-10% |
Trans. Date |
Form |
Action |
Price |
Mkt Value |
D/I |
Shares |
Holdings |
Rank
|
|
|
| 3m +/- |
|
|
Form |
| EDIT |
Editas Medicine, Inc. |
CEO |
• • – |
2024-03-05 |
4 |
S |
$9.42 |
$732,884 |
D/D |
(77,824) |
327,470 |
0 |
% |
|
| EDIT |
Editas Medicine, Inc. |
CEO |
• • – |
2024-03-02 |
4 |
A |
$0.00 |
$0 |
D/D |
275,125 |
405,294 |
0 |
- |
|
| EDIT |
Editas Medicine, Inc. |
CEO |
• • – |
2023-06-05 |
4 |
S |
$9.50 |
$61,638 |
D/D |
(6,486) |
130,169 |
0 |
% |
|
| EDIT |
Editas Medicine, Inc. |
CEO |
• • – |
2023-03-02 |
4 |
A |
$0.00 |
$0 |
D/D |
50,000 |
136,655 |
0 |
- |
|
| EDIT |
Editas Medicine, Inc. |
CEO |
• • – |
2022-06-02 |
4 |
A |
$0.00 |
$0 |
D/D |
86,655 |
86,655 |
0 |
- |
|
| SRPT |
Sarepta Therapeutics Inc |
EVP, R&D & CMO |
• – – |
2021-03-03 |
4/A |
A |
$0.00 |
$0 |
D/D |
15,000 |
28,546 |
0 |
- |
|
| SRPT |
Sarepta Therapeutics Inc |
EVP, R&D & CMO |
• – – |
2021-03-03 |
4 |
A |
$0.00 |
$0 |
D/D |
15,000 |
29,070 |
0 |
- |
|
| SRPT |
Sarepta Therapeutics Inc |
EVP, R&D & CMO |
• – – |
2021-02-28 |
4/A |
D |
$86.97 |
$45,572 |
D/D |
(524) |
13,546 |
0 |
- |
|
| SRPT |
Sarepta Therapeutics Inc |
EVP, R&D & CMO |
• – – |
2020-02-28 |
4 |
A |
$0.00 |
$0 |
D/D |
6,700 |
14,070 |
0 |
- |
|
| SRPT |
Sarepta Therapeutics Inc |
EVP, R&D & CMO |
• – – |
2019-05-24 |
4 |
D |
$119.31 |
$552,405 |
D/D |
(4,630) |
7,370 |
0 |
- |
|
| SRPT |
Sarepta Therapeutics Inc |
EVP, R&D & CMO |
• – – |
2019-05-23 |
4 |
OE |
$0.00 |
$0 |
D/D |
12,000 |
12,000 |
0 |
- |
|
11 Records found
|
1
|
Page 1 of 1 |
| |
Free Registration Required For Full Results. Limit: 25
|
|
| |
Transaction Code Key: |
Ownership Code Key |
| |
B |
- Buy |
AB |
- Automatic Buy |
D |
- Direct Ownership |
| |
S |
- Sell |
AS |
- Automatic Sell |
I |
- Indirect Ownership |
|
OE |
- Options Exercised |
A |
- Aquired |
| |
IO |
- Initital Ownership |
D |
- Disposed |
| |
|
|
|
|
|
